Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.
Great Lakes Center of Rheumatology, Lansing, Michigan.
Arthritis Rheumatol. 2023 Dec;75(12):2185-2194. doi: 10.1002/art.42652.
Obexelimab is an investigational, bifunctional, noncytolytic monoclonal antibody that binds CD19 and FcyRIIb to inhibit B cells, plasmablasts, and plasma cells. This trial evaluated the efficacy and safety of obexelimab in the treatment of patients with systemic lupus erythematosus (SLE).
During screening, patients with active, non-organ-threatening SLE received corticosteroid injections to ameliorate symptoms while immunosuppressants were withdrawn (≤10 mg/day prednisone equivalent and ≤400 mg/day hydroxychloroquine allowed). Patients with improved disease activity were randomized 1:1 to obexelimab 5 mg/kg intravenously or placebo once every 2 weeks until week 32 or loss of improvement (LOI).
In this study, 104 patients were randomized. Analysis of the primary endpoint, proportion of patients reaching week 32 without LOI, used an efficacy-evaluable (EE) population defined as patients who completed the study or withdrew for flare or treatment-related toxicity. This endpoint did not reach statistical significance: 21 of 50 obexelimab-treated patients (42.0%) versus 12 of 42 patients (28.6%) treated with a placebo (P = 0.183). Time to LOI was increased in obexelimab-treated patients versus patients treated with a placebo in the EE (hazard ratio [HR] 0.53, P = 0.025) and intention-to-treat (HR 0.59, P = 0.062) populations. In obexelimab-treated patients, B cells decreased approximately 50%, and trough concentration and inclusion in baseline gene expression clusters with high B cell pathway modules were associated with increased time to LOI. Obexelimab was associated with infusion reactions but was generally safe and well-tolerated.
Although the primary endpoint was not reached, secondary analysis showed time to LOI was significantly increased in obexelimab-treated patients, and analysis of patient subsets defined by gene expression patterns at baseline suggests a responding subpopulation.
Obexelimab 是一种研究性的、双功能的、非溶细胞性单克隆抗体,它可以结合 CD19 和 FcyRIIb 来抑制 B 细胞、浆母细胞和浆细胞。本试验评估了 obexelimab 治疗系统性红斑狼疮(SLE)患者的疗效和安全性。
在筛选期间,患有活动性、非器官威胁性 SLE 的患者接受皮质类固醇注射以改善症状,同时停用免疫抑制剂(允许 ≤10 mg/天泼尼松等效物和 ≤400 mg/天羟氯喹)。疾病活动改善的患者以 1:1 的比例随机分为 obexelimab 5mg/kg 静脉注射或安慰剂,每 2 周一次,直至第 32 周或失去改善(LOI)。
在这项研究中,104 名患者被随机分组。主要终点的分析,即达到无 LOI 的第 32 周的患者比例,使用了一个疗效可评估(EE)人群,该人群定义为完成研究或因病情加重或治疗相关毒性而退出的患者。该终点未达到统计学意义:obexelimab 治疗组 50 名患者中有 21 名(42.0%),安慰剂组 42 名患者中有 12 名(28.6%)(P = 0.183)。EE 中,与安慰剂组相比,obexelimab 治疗组的 LOI 时间增加(风险比[HR]0.53,P = 0.025)和意向治疗(HR 0.59,P = 0.062)人群。在 obexelimab 治疗组中,B 细胞减少约 50%,而浓度谷值和基线基因表达聚类中的纳入与 LOI 时间的增加有关。Obexelimab 与输注反应有关,但总体上是安全且耐受良好的。
尽管主要终点未达到,但二次分析显示 obexelimab 治疗组的 LOI 时间显著增加,并且基于基线基因表达模式的患者亚组分析表明存在一个应答亚群。